Restricted cash of $ 0.3 million was held as collateral to secure the use of corporate cards under a cash pledge agreement entered into in December 2024.

filing / Aug 6, 2026 / receipt

We initiated that reduction in force impacting approximately 25 employees across the organization. On October 21, 2025, we committed to a plan to reduce our workforce by approximately 47% in order to align resources with the Company’s strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial evaluating the safety and efficacy of latozinemab (AL001) in individuals with

filing / Aug 6, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.

filing / Aug 6, 2026 / receipt

We initiated a reduction in force in October 2025 that impacted approximately 47% of our workforce. Total incremental restructuring charges associated with the reduction in force are approximately $7.0 million, consisting primarily of severance and related termination benefits.

filing / Aug 6, 2026 / receipt

Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

filing / Aug 6, 2026 / receipt

On March 7, 2025, the Company committed to a plan to reduce its workforce by approximately 13 % as part of its cost reduction initiatives in order to align resources with the Company’s strategic priorities, including advancing its preclinical and research pipeline.

filing / Aug 6, 2026 / receipt

Restricted cash of $ 0.3 million was held as collateral to secure the use of corporate cards under a cash pledge agreement entered into in December 2024.

filing / May 7, 2026 / receipt

We initiated that reduction in force impacting approximately 25 employees across the organization. On October 21, 2025, we committed to a plan to reduce our workforce by approximately 47% in order to align resources with the Company’s strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial evaluating the safety and efficacy of latozinemab (AL001) in individuals with frontotemporal dementia

filing / May 7, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.

filing / May 7, 2026 / receipt

We initiated a reduction in force in October 2025 that impacted approximately 47% of our workforce. Total incremental restructuring charges associated with the reduction in force are approximately $7.0 million, consisting primarily of severance and related termination benefits.

filing / May 7, 2026 / receipt

Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

filing / May 7, 2026 / receipt

On March 7, 2025, the Company committed to a plan to reduce its workforce by approximately 13 % as part of its cost reduction initiatives in order to align resources with the Company’s strategic priorities, including advancing its preclinical and research pipeline.

filing / May 7, 2026 / receipt